PROGRAMME DE DOSAGE DESTINE A UNE COMBINAISON DE CERITINIB ET D'UNE MOLECULE D'ANTICORPS ANTI-PD -1

• 收藏
• 分享

专利权人:

NOVARTIS AG;BRISTOL-MYERS SQUIBB

发明人:

SCOTT, JEFFREY

申请号：

CA3053469

公开号：

CA3053469A1

申请日:

2018.02.26

申请国别(地区):

CA

年份:

2018

代理人:

摘要：

The present disclosure relates to the field of pharmacy, particularly to ceritinib and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising ceritinib, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/